Enduro Genetics continues to scale cell-reprogramming tech for industrial bioproduction

Enduro Genetics, a Denmark-based synthetic biology company pioneering scalable microbial bioproduction, which announced in February 2025, that is had raised €12 million (approximately US$13 million) in a Series A round led by Supernova Invest, NOON Ventures, and Sandwater, is continuing its goal to expand and commercialize its patented Enduro Sense technology, which reprograms microbial cells to maintain high productivity throughout industrial fermentation processes.

At the heart of Enduro’s innovation is its synthetic 'addiction' approach: a genetic plug-in that links a microbe’s ability to grow and thrive directly to its productivity. This solves a long-standing challenge in biomanufacturing – the loss of yield over time due to cell-to-cell variation and the emergence of non-productive cells that outcompete their productive counterparts.

“Solving the cell-to-cell biomanufacturing challenge has plagued academia and industry for decades,” commented Peter Rugbjerg, Founder & Chief Scientific Officer of Enduro Genetics. “Too many companies have been limited by the fact that only a minority of cells used in bioprocesses today contribute to high production. At Enduro, we’re redefining bioprocesses with a new optimization technology to unlock biotechnology’s full potential.”

Enduro’s platform technology is applicable across a broad spectrum of microbial hosts and production systems, from biopharmaceuticals to industrial enzymes, bioplastics, alternative proteins, and specialty chemicals. It can be integrated into both established and new processes, offering a flexible solution to clients seeking greater yield, reduced production costs, and improved carbon performance.

CEO Christian Munch called the latest investment “a key milestone” for the company. “It is a testament to the team, the impact potential of our technology and the market validation we have achieved over the last two years. The funding allows us to accelerate our commercialization efforts, strengthen our technology platform and expand the technology for use in biopharmaceutical expression systems.”

Enduro’s total funding now stands at €18 million, including previous support from the BioInnovation Institute and the European Innovation Council Accelerator grant. The company is already working with leading partners in biopharma, food, agriculture, and industrial sectors to implement Enduro Sense across a variety of use cases.

The synthetic addiction model has been validated through Rugbjerg’s published research in journals such as Nature and PNAS, and is now gaining traction among industry players looking for reliable solutions to scale bioproduction sustainably.

Romain Sautrau, Investment Director at Supernova Invest, said the firm sees Enduro’s technology as a critical enabler of cost-effective biomanufacturing. “We were impressed not only with the technology but also the team's traction in such a short time bringing on board leading biomanufacturing companies. Enduro’s novel technology could act as a critical enabler to break the cost barrier of biosolutions for a massive application into the food and chemical industries.”

Theis Malmborg, General Partner at NOON Ventures, added: “Enduro’s cell reprogramming technology is solving major challenges in the bioproduction space and large organizations are already starting to reap the benefits. We believe the team will have an outsized impact on the future of biomanufacturing.”

As industries increasingly seek to transition away from fossil-derived inputs, biomanufacturing is expected to play a central role in sustainable production. By ensuring that microbial populations remain productive throughout fermentation, Enduro aims to make biological production more viable, resilient, and cost-effective at industrial scale.

Enduro was spun out of the Technical University of Denmark and continues to grow its platform as a modular tool for enabling next-generation bioprocesses. The company is actively seeking additional industry partnerships and will use the Series A funds to build out its team and expand its market reach across Europe and North America.